To determine whether Pdgfrβ and Pkcα activity represented therapeutic target in BRCA1-deficient tumors, we treated p18−/−;Brca1MGKO tumor cells with a PDGFR Inh III and PKCα inhibitor, Ro-31-8220. Here, PDGFRB is linked to neoplasm.